Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin B3 five-year diabetes prevention trial enrollment near completion.

This article was originally published in The Tan Sheet

Executive Summary

VITAMIN B3 FIVE-YEAR, MULTI-CENTER DIABETES MELLITUS TRIAL has nearly completed enrollment. The Canadian/European Niacinamide Diabetes Intervention Trial (CAN ENDIT) will test the effectiveness of niacinamide, a derivative of vitamin B3, in delaying the onset of Type I diabetes in approximately 500 subjects at high risk for the disease.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086254

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel